These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32394752)

  • 21. A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey.
    Späth HM; Charavel M; Morelle M; Carrere MO
    Pharm World Sci; 2003 Dec; 25(6):269-75. PubMed ID: 14689815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation and the Jordan Rational Drug List: an exploratory study of national-level priority setting.
    Lafi R; Robinson S; Williams I
    Value Health; 2012; 15(5):771-6. PubMed ID: 22867788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature.
    Sanchez LA
    Am J Health Syst Pharm; 1999 Aug; 56(16):1630-8; quiz 1638-40. PubMed ID: 10459385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of pharmacoeconomics in current Indian healthcare system.
    Ahmad A; Patel I; Parimilakrishnan S; Mohanta GP; Chung H; Chang J
    J Res Pharm Pract; 2013 Jan; 2(1):3-9. PubMed ID: 24991597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomics and the quality of decision-making by pharmacy and therapeutics committees.
    Langley PC
    Am J Health Syst Pharm; 1995 Jul; 52(14 Suppl 3):S24-6. PubMed ID: 7552914
    [No Abstract]   [Full Text] [Related]  

  • 28. A pharmacoeconomics and formulary management collaborative project to teach decision analysis principles.
    Cavanaugh TM; Buring S; Cluxton R
    Am J Pharm Educ; 2012 Aug; 76(6):115. PubMed ID: 22919091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications.
    Matlala M; Gous AG; Godman B; Meyer JC
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1273-1280. PubMed ID: 28776442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A qualitative study exploring perceptions and attitudes of community pharmacists about extended pharmacy services in Lahore, Pakistan.
    Hashmi FK; Hassali MA; Khalid A; Saleem F; Aljadhey H; Babar ZUD; Bashaar M
    BMC Health Serv Res; 2017 Jul; 17(1):500. PubMed ID: 28724411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospital pharmacy medication reconciliation practice in Jordan: perceptions and barriers.
    Hammour KA; Farha RA; Basheti I
    J Eval Clin Pract; 2016 Dec; 22(6):932-937. PubMed ID: 27198470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.
    Reeder CE
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The State of Pharmacoeconomics Education in the Doctor of Pharmacy Curriculum amid the Changing Face of Pharmacy Practice.
    Adunlin G; Skiera J; Cupp CS; Ali AA; Afeli SAY
    Healthcare (Basel); 2023 Nov; 11(22):. PubMed ID: 37998415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach.
    Finder S
    Clin Ther; 1997; 19(1):160-6. PubMed ID: 9182021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The introduction of pharmacoeconomic analysis in Norway--are the users prepared?
    Rørvik EM; Toverud EL; Walløe L
    Pharm World Sci; 2001 Aug; 23(4):135-44. PubMed ID: 11599199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-perceived barriers and facilitators to the implementation of a medication review in primary care: a qualitative thematic analysis.
    Uhl MC; Muth C; Gerlach FM; Schoch GG; Müller BS
    BMC Fam Pract; 2018 Jan; 19(1):3. PubMed ID: 29304725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluations of health technologies in Dutch healthcare decision-making: a qualitative study of the current and potential use, barriers, and facilitators.
    Roseboom KJ; van Dongen JM; Tompa E; van Tulder MW; Bosmans JE
    BMC Health Serv Res; 2017 Jan; 17(1):89. PubMed ID: 28126005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making.
    Drummond M; Brown R; Fendrick AM; Fullerton P; Neumann P; Taylor R; Barbieri M;
    Value Health; 2003; 6(4):407-16. PubMed ID: 12859580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penny and pound wise: pharmacoeconomics from a governmental perspective.
    van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
    Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.